fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Search » Divi's Laboratories Ltd

Divi s Laboratories Ltd

Updated on January 15, 2020

Stock/Share Code - DIVISLAB

Divis Laboratories is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business...Read more

Below is the details of DIVISLAB Divi s Laboratories Ltd

Market Cap₹47,418 Cr.
Current Price ₹1,813.65 as on 10 Dec 19
52 Week High / Low Price₹1,825 / ₹1,420.05
Face Value₹2
Stock P/E36.79
Book Value₹262.68
Dividend Yield0.90 %
ROCE27.66 %
ROE20.32 %
Sales Growth (3yrs)9.47 %
SectorPharmaceuticals
IndustryPharmaceuticals - Indian - Bulk Drugs
Listed onBSE  AND  NSE
Company WebsiteCompany Website
Pros: Company is virtually debt free. Company has been maintaining a healthy dividend payout of 29.20%
Cons:

Divi s Laboratories Ltd Price Chart

Divi s Laboratories Ltd Price Chart

Divi s Laboratories Ltd Peer Comparison in Pharmaceuticals

S.No. Name CMP Rs. P/E Mar Cap Rs.Cr. Div Yld % NP Qtr Rs.Cr. Qtr Profit Var % Qtr Sales Var % Sales Qtr Rs.Cr. ROCE %
1. Divi's Lab. ₹152.9 36.79 ₹47,418 Cr. 0.90 ₹352.83 Cr. -11.27 9.25 1403.92 27.66
2. Lupin ₹752.8 40.33 ₹36,248.21 Cr. 0.62 -₹127.07 Cr. 37.05 10.34 4359.65 9.97
3. Vinati Organics ₹1,952.7 29.60 ₹10,230.41 Cr. 0.35 ₹110.01 Cr. 69.17 -1.48 245.06 45.83
4. Jubilant Life ₹520.25 10.56 ₹8,127.49 Cr. 0.88 ₹249.39 Cr. 15.31 -0.16 2265.93 16.37
5. Suven Life Scie. ₹265.25 27.34 ₹4,007.49 Cr. 0.48 ₹63.31 Cr. 1535.92 206.42 274.31 16.95
6. Granules India ₹124.9 10.71 ₹3,248.01 Cr. 0.78 ₹95.79 Cr. 58.96 20.43 699.53 14.75
7. Shilpa Medicare ₹287.9 23.21 ₹2,471.9 Cr. 0.33 ₹50.78 Cr. 123.21 78.65 289.92 8.74
8. Sequent Scien. ₹66.55 26.75 ₹1,682.43 Cr. 0.29 ₹21.29 Cr. 39.79 12.91 284.22 9.21

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Divi s Laboratories Ltd Fundamentals

Quarterly Results

Quarterly reports are issued by companies every three months. Most companies have a financial year-end of Mar. 31 and quarters that end on June 30, Sept. 30, Dec. 31 and March 31.

Standalone Figures in Rs. Crores

Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019
Sales9761,0678218901,0381,0889951,2851,3431,2561,1401,404
YOY Sales Growth %13.58%-3.33%-19.27%-11.46%6.29%1.99%21.2%44.35%29.39%15.49%14.53%9.25%
Expenses599705576613712701643771820845761919
Material Cost %35.91%39.47%40.38%40.14%39.35%37.47%38.32%36.83%35.76%40.03%39.8%41.13%
Employee Cost %10.59%9.95%12.26%11.77%11.08%11.56%12.19%10.48%10.16%11.01%12.1%10.51%
Operating Profit378362245277326386352514523411379485
OPM %39%34%30%31%31%36%35%40%39%33%33%35%
Other Income222130341748498035423247
Interest01010-0103004
Depreciation313132343739424242424446
Profit before tax368350242276306396358552513410366483
Tax %27%26%27%25%26%34%26%28%26%29%27%27%
Net Profit268259177207225262266398379289267353
EPS in Rs10.119.776.657.798.469.8510.0314.9814.2910.9010.0713.29
NotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotes

Profit & Loss

The profit and loss (P&L) statement is a financial statement that summarizes the revenues, costs and expenses incurred during a specified period, usually a fiscal quarter or year. The P&L statement is synonymous with the income statement. These records provide information about a company's ability or inability to generate profit" by increasing revenue, reducing costs or both. Some refer to the P&L statement as a statement of profit and loss, income statement, statement of operations, statement of financial results or income, earnings statement or expense statement.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019TTM
Sales1,0331,1919291,3151,8452,1292,5143,0843,7204,0243,8164,8805,143
Sales Growth %42.43%15.28%-21.98%41.49%40.31%15.39%18.09%22.67%20.63%8.17%-5.17%27.88%%
Expenses6167015178091,1491,3061,4921,9142,3142,5832,5613,0303,345
Material Cost %39.85%37.29%31.85%40.35%41.92%37.47%36.52%39.41%40.17%39.12%39.44%37.66%%
Manufacturing Cost %6.47%6.81%7.99%7.2%6.99%9.49%9.18%8.93%8.47%7.64%10.15%8.73%%
Employee Cost %4.16%4.91%7.16%8.52%7.87%8.98%8.97%9.18%9.49%12.19%11.69%10.88%%
Other Cost %9.17%9.83%8.68%5.49%5.52%5.43%4.67%4.54%4.09%5.25%5.83%4.81%%
Operating Profit4174904125056968231,0221,1701,4061,4401,2551,8501,798
OPM %40%41%44%38%38%39%41%38%38%36%33%38%35%
Other Income14233129664981369274109157155
Interest10732533343257
Depreciation36485153627792136118123142169175
Profit before tax3854583884796957921,0091,0671,3751,3881,2191,8331,772
Tax %8%7%11%9%21%23%22%21%19%24%29%27%
Net Profit3544243444365466117928471,1111,0538701,3331,289
EPS in Rs2.7116.1312.5215.6119.5121.7528.1229.8741.8439.6832.7650.2048.55
Dividend Payout %7%9%23%30%32%33%34%31%24%25%31%32%

Compounded Sales Growth

  • 10 Years:: 15.14%
  • 5 Years:: 14.18%
  • 3 Years:: 9.47%
  • TTM:: 16.73%

Compounded Profit Growth

  • 10 Years:: 11.96%
  • 5 Years:: 10.61%
  • 3 Years:: 5.65%
  • TTM:: 12.08%

Return on Equity

  • 10 Years:: 18.62%
  • 5 Years:: 15.57%
  • 3 Years:: 15.80%
  • 1 Year:: 24.10%

Balance Sheet

A balance sheet is a financial statement that reports a company's assets, liabilities and shareholders' equity at a specific point in time, and provides a basis for computing rates of return and evaluating its capital structure. It is a financial statement that provides a snapshot of what a company owns and owes, as well as the amount invested by shareholders. It is used alongside other important financial statements such as the income statement and statement of cash flows in conducting fundamental analysis or calculating financial ratios.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Share Capital131326272727272753535353
Equity Capital12.9112.9526.4326.5226.5526.5526.5526.5553.0953.0953.0953.09
Reserves8611,2491,5161,8022,1482,5273,0083,5354,3045,3565,9076,920
Borrowings8653332355331827423663106
Other Liabilities237260313460574612731886640807798973
Trade Payables149.73155.66157.56121.24157.31180.04164.47246.74313.9467.81427.15523.04
Total Liabilities1,1971,5751,8882,3112,8053,1983,7844,4755,0406,2526,8218,052
Fixed Assets4975905905907389081,2221,3091,4391,5591,9962,087
Gross Block641.92782.49832.65885.341091.631337.881739.791952.42195.421793.572372.922633.29
Accumulated Depreciation145.05192.82242.98295.61353.44429.38518.19643.67756.78234.62377.04545.85
CWIP632024104182303144218264444120492
Investments561724425284804115057368131,6391,8971,953
Other Assets5817938331,0891,4051,5751,9132,2122,5242,6102,8093,519
Inventories275.65395.91479.57543.07650.97805.95893.271114.91162.891255.761281.391663.18
Trade receivables214.24283.5234.44392.78533.97558.9791.64823.03966.121002.891112.111282.24
Cash Equivalents12.6112.8712.8712.821.8234.6835.7756.6659.3866.4791.48105.2
Loans n Advances78.22100.82106.1462.7669.1368.6156.8668.38140.88125.01192.89210.07
Other Assets etc00077.41128.62107.27135.65149.07194.65160.04130.86258.72
Total Assets1,1971,5751,8882,3112,8053,1983,7844,4755,0406,2526,8218,052

Cash Flows

Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Cash from Operating Activity3023013683263344835588221,0361,149765964
Profit from operations444.25551.7409.7503.17715.94846.591078.71175.511444.571469.331249.081919.94
Working Capital Changes-106.8-211.8212.48-143.79-259.15-189.3-307.22-141.64-147.34-18.52-215.81-472.96
Taxes paid-35.34-39.09-54.51-33.42-122.74-174.46-213.33-211.43-260.89-301.7-268.55-482.92
Cash from Investing Activity-235-217-317-222-204-254-305-521-411-1,137-476-684
Fixed Assets Purchased-171.05-110.33-60.17-162.63-289.12-340.03-246.37-307.14-395.71-376.53-273.87-732.94
Fixed Assets Sold0.110.030.340.010.0369.220.090.0500.050.130.02
Investments purchased-55.57-167.11-314.38-668.32-51.6500-231.13-69.52-1252.06-745-864.04
Investments sold050.8744.91583.86100.350-94.060-2.39424.99489.11834.96
Cash from Financing Activity-65-82-48-104-131-231-248-303-6303-314-246
Proceeds from Shares04.0226.284.511.390000000
Proceeds from Borrowings003.378.0336.58008.750000
Repayment of Borrowings-67.87-33.44-23.16-17.84-2.36-22.37-14.64-0.5516.35000
Interest Paid-7.95-4.17-1.28-0.68-2.51-0.77-0.91-0.57-1.65-2.25-1.33-3.5
Dividends Paid0-30.27-45.52-92.45-154.17-200.55-232.95-310.59-639.020-319.25-320.04
Net Cash Flow213-0-1-25-1-515-2534

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Ratios

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
ROCE %48%41%27%28%34%33%36%32%35%28%21%28%
Debtor Days7687921091069611597959110696
Inventory Turnover4.253.552.122.573.092.922.963.073.273.333.013.31

Announcements & News

Recent Announcements

How to Invest in Mutual Funds SIP Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.
  2. Complete your Registration and KYC Process
  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest! Get Started
  4. Invest in Mutual Funds which invests in Divi s Laboratories Ltd & Get More Returns than Bank Deposit

Disclaimer:
All efforts have been made to ensure the information provided here is accurate as per time to time filling by company to exchanges. However, no guarantees are made regarding correctness of data. Investors are advised to validate/check information with exchanges or companies website before making any investment decisions.